Description

Cagrillintide / GLP-1 S (Dual Pathway Blend)

The Cagrillintide / GLP-1 S blend represents the next generation of metabolic research. It is a precise formulation combining two potent agonists: Cagrillintide, a long-acting amylin analogue, and GLP-1 S (Semaglutide), a glucagon-like peptide-1 receptor agonist. Unlike other blends that target the same family of receptors, this combination engages two distinct physiological pathways to maximize metabolic efficacy.

At Guardian Labs, we have engineered this blend to provide researchers with a convenient, pre-mixed solution for investigating the “additive” effects of amylin and incretin biology. Every vial is HPLC-verified to ensure >99% purity and accurate constituent ratios.

What is Cagrillintide / GLP-1 S?

This blend mimics the emerging pharmaceutical candidate known as “CagriSema.” It combines:

1. Cagrillintide: A synthetic analogue of the hormone Amylin. In nature, amylin is co-secreted with insulin by the pancreas. It functions primarily to induce satiety and slow gastric emptying.

2. GLP-1 S (Semaglutide): A GLP-1 receptor agonist that enhances insulin secretion, suppresses glucagon, and signals satiety to the brain.

By combining them, researchers can study how simultaneous activation of the Amylin and GLP-1 receptors affects body weight and glycemic control more effectively than either compound alone.

Mechanism of Action: The “Additive” Effect

The power of the Cagrillintide / GLP-1 S blend lies in its non-overlapping mechanisms:

• The Amylin Pathway (Cagrillintide): Binds to amylin receptors (AMY1, AMY3) in the hindbrain. This signaling pathway is distinct from the incretin system and is responsible for “meal termination” signaling (feeling full sooner) and regulating the speed at which food leaves the stomach.

• The Incretin Pathway (GLP-1): Binds to GLP-1 receptors in the pancreas and hypothalamus. This improves glucose-dependent insulin secretion and reduces appetite via central nervous system signaling.

Synergy: Research suggests that because these two peptides hit different receptors in different parts of the brain/gut axis, their effects are additive—potentially breaking through the “plateaus” often seen with GLP-1 mono-therapy.

Potential Research Applications

This blend is currently the subject of high-profile clinical investigation. Key areas of interest include:

• Obesity & Weight Management: Studies are comparing this blend directly against Tirzepatide and Semaglutide alone to measure superior weight reduction efficacy.

• Type 2 Diabetes: Investigating the dual capability of lowering HbA1c through insulin modulation (GLP-1) and glucagon suppression (Amylin).

• Gastric Emptying Rates: Researching how the combination influences gastric motility and nutrient absorption rates.

  ---

Scientific References

To validate the potential of this specific combination, we reference the following pivotal studies.

1. Efficacy of CagriSema vs. Mono-therapy

Summary: This phase 2 clinical trial (published in The Lancet) investigated the combination of Cagrillintide and Semaglutide in patients with type 2 diabetes. The results showed that the combination group achieved significantly greater weight loss (-15.6%) compared to the Semaglutide-only group (-5.1%) and the Cagrillintide-only group (-8.1%).

• View the study on PubMed

2. Biology of Amylin Analogues

Summary: This research outlines the pharmacology of Cagrillintide. It highlights how the long-acting amylin analogue effectively reduces food intake and body weight through specific amylin receptor agonism, validating its role as a necessary partner to GLP-1 therapies.

• View the study on PubMed

3. Synergistic Metabolic Control

Summary: Preclinical studies in rodent models demonstrated that co-administration of Amylin and GLP-1 analogues leads to a synergistic reduction in food intake. The data suggests that engaging the amylin system can overcome compensatory mechanisms that typically limit the long-term effectiveness of GLP-1 agonists.

• View the study on PubMed

  ---

Product Specifications

• Components: Cagrillintide & Semaglutide (GLP-1 S)

• Format: Lyophilized Powder (Freeze-dried)

• Purity: >99% (HPLC Verified)

• Solubility: Water Soluble

• Storage: Store at -20°C. Reconstitute with Bacteriostatic Water.

  ---

  Disclaimer: All products listed on this site are for laboratory research and development purposes only. They are not intended for human consumption, diagnostic, or therapeutic use. Customers must be at least 18 years old to purchase.